Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model

Gozukara I., Dokuyucu R., Ozgur T., Ozcan O., Pinar N., Kurt R. K., ...Daha Fazla

GYNECOLOGICAL ENDOCRINOLOGY, cilt.32, sa.6, ss.492-497, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.3109/09513590.2015.1134478
  • Dergi Adı: GYNECOLOGICAL ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.492-497
  • Anahtar Kelimeler: Histopathology, polycystic ovary syndrome, treatment, ursodeoxycholic acid, POLYCYSTIC-OVARY-SYNDROME, FATTY LIVER-DISEASE, INSULIN-RESISTANCE, METFORMIN, MECHANISMS, WOMEN, METAANALYSIS
  • Marmara Üniversitesi Adresli: Hayır

Özet

The aim of this study was to determine the effect of ursodeoxycholic acid (UDCA) treatment on a polycystic ovary syndrome (PCOS) rat model. Thirty-two female Wistar-Albino rats were randomly divided into four groups as follows - group 1: sham group (n: 8), group 2: letrozole-induced PCOS group (n: 8), group 3: letrozole-induced PCOS plus metformin-treated (500 mg/kg) group (n: 8) and group 4: letrozole-induced PCOS plus UDCA (150 mg/kg)-treated group (n: 8). Histopathologic examination of the ovaries, circulating estrone (E1), estradiol (E2), testosterone, androstenedione, glucose, insulin and lipid profiles were evaluated. Histopathologic examination results revealed that groups 3 and 4 had significantly lower cystic and atretic follicles compared to group 2. Besides, group 4 had significantly higher antral follicles than group 2 (8.5 +/- 2.9 versus 5.4 +/- 1.1; p: 0.001). Furthermore, total testosterone (4.9 +/- 2.8 versus 8.8 +/- 2.9; p=0.004) and insulin levels were significantly lower in group 4 compared to group 2 (1.7 +/- 0.08 versus 2.1 +/- 0.5; p = 0.02). However, lipid parameters, E1, E2, glucose and HOMA-IR were comparable between the groups. Our study results demonstrated that UDCA therapy improves ovarian morphology and decreases total testosterone and insulin levels.